Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | ARG2 | P78540 | 1/20 | 0.52 |
| ▸ | TOP1 | P11387 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40701 | 1.00 | MAOB (0.70) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL105172 | 1.00 | MAOB (0.70) | MAOBCA1CA2ARG2TOP1 | |
| Benzene SCHEMBL1226362 | 1.00 | MAOB (0.70) | MAOBCA1CA2ARG2TOP1 | |
| Benzene SCHEMBL1226361 | 1.00 | MAOB (0.70) | MAOBCA1CA2ARG2TOP1 | |
| Butane SCHEMBL28785258 | 0.93 | MAOB (0.61) | MAOBCA1CA2ARG2TOP1 | |
| Bicarbonate SCHEMBL32684914 | 0.91 | MAOB (0.58) | MAOBCA1CA2ARG2TOP1 | |
| Methenamine SCHEMBL9467271 | 0.87 | MAOB (0.54) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL15466749 | 0.83 | MAOB (0.61) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL15466750 | 0.83 | MAOB (0.61) | MAOBCA1CA2ARG2TOP1 | |
| SCHEMBL1524697 | 0.83 | MAOB (1.00) | MAOBCA1CA2ARG2TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-7619125-B2 | Hydrogenation promoter, hydrogenation catalyst, and process for producing alkene compound | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20080033221-A1 | Hydrogenation Promoter, Hydrogenation Catalyst, and Process for Producing Alkene Compound | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| CN-1214860-C | Composition and its preparation method | KURARAY CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| US-6929787-B2 | Composite and manufacturing method thereof | KURARAY CO., LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| CN-1381307-A | Composition and its preparation method | KURARAY CO (JP) | 2002-11-27 | — | — | CN | disclosed |
| EP-1232788-A2 | Composite product and manufacturing method thereof | Kuraray Co., Ltd. (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-20020111269-A1 | Composite and manufacturing method thereof | KURARAY CO. LTD. (JP) | 2002-08-15 | — | — | US | disclosed |
| US-4822937-A | CATALYTIC ALKYLATION, THEN DEHYDROISOMERIZATION | BP CHEMICALS LIMITED (GB) | 1989-04-18 | — | — | US | disclosed |
| EP-0196165-B1 | PROCESS FOR THE PRODUCTION OF ISOBUTYLBENZENES | BP Chemicals Limited (GB) | 1988-05-04 | — | — | EP | disclosed |
| EP-0196165-A1 | Process for the production of isobutylbenzenes | BP Chemicals Limited (GB) | 1986-10-01 | — | — | EP | disclosed |
| WO-1986004892-A1 | PROCESS FOR THE PRODUCTION OF ISOBUTYLBENZENES | BP CHEMICALS LIMITED (GB) | 1986-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | MAOB 157/4885CA1 2395/4885CA2 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.